Heart failure & cardiomyopathies
Characteristics and Outcome of Patients With a History of Cancer Undergoing Durable Left Ventricular Assist Device Implantation
Authors' conclusion
A history of cancer is associated with mildly reduced survival, lower incidence of heart transplantation, and increased risk of bleeding after LVAD, whereas the survival in patients with cancer with CCM-induced heart failure is similar to those without cancer.
Study context
- Population
- Adults receiving durable left ventricular assist device (LVAD), INTERMACS registry, 2008–20171,273 (6.5%) with cancer history
- Exposure
- History of cancer vs no cancer in durable LVAD recipients
- Cancern = 1,273
- Outcome
- Survival
Methodological detailsINTERMACS registry, multivariable Cox and competing risk regressions
- INTERMACS registry
- Multivariable Cox and competing risk regressions
Main finding
As reported in the abstract
Cancer vs No cancerEstimate (95% CI)P value
Multivariable Cox
HR 1.14(1.04–1.26)
P = 0.005Competing risk regression
subdistribution HR 1.24(1.13–1.36)
P < 0.001Observational data: associations, not effects.
Further findings
Heart transplantation
- Cancer history associated with decreased incidence of heart transplantation
Mortality, CCM-induced HF vs no cancer (subgroup)
- No significant difference in mortality between CCM-induced HF and no cancer
- CCM n = 289 (22.7%); non-CCM n = 984 (77.3%)
Predictors of mortality in cancer patients
- Age, INTERMACS profile, albumin, dialysis and blood urea nitrogen associated with mortality
Original publication
Characteristics and Outcome of Patients With a History of Cancer Undergoing Durable Left Ventricular Assist Device Implantation. Circ Heart Fail. Published 14 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →